Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
49
NEUE Quote, Financials, Valuation and Earnings
Last price:
$6.87
Seasonality move
:
-36.31%
Day range:
$6.81 - $6.94
52-week range:
$3.79 - $7.66
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.06x
P/B ratio:
--
Volume:
4K
Avg. volume:
6.6K
1-year change:
32.43%
Market cap:
$61.2M
Revenue:
$936.7M
EPS (TTM):
-$22.00
Analysts' Opinion
-
Consensus RatingNeueHealth has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.00, NeueHealth has an estimated upside of 2.04% from its current price of $6.86.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.00 representing 100% downside risk from its current price of $6.86.
Fair Value
-
According to the consensus of 1 analyst, NeueHealth has 2.04% upside to fair value with a price target of $7.00 per share.
NEUE vs. S&P 500
-
Over the past 5 trading days, NeueHealth has overperformed the S&P 500 by 0.38% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
NeueHealth does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
NeueHealth revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter NeueHealth reported revenues of $215.8M.
Earnings Growth
-
NeueHealth has grown year-over-year earnings for 0 quarters straight. In the most recent quarter NeueHealth reported earnings per share of -$2.90.
Enterprise value:
1.1B
EV / Invested capital:
--
Price / LTM sales:
0.06x
EV / EBIT:
--
EV / Revenue:
1.20x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-11.06x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$201.2M
Return On Assets:
-15.76%
Net Income Margin (TTM):
-14.38%
Return On Equity:
-3241.93%
Return On Invested Capital:
-1375.06%
Operating Margin:
1.23%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $870.9M | $1.1B | $907.3M | $245.1M | $215.8M | |
| Gross Profit | $127.3M | $172M | $201.2M | $48.2M | $54.9M | |
| Operating Income | -$238M | -$120.4M | -$69.2M | -$23.1M | $2.7M | |
| EBITDA | -$255.8M | -$518M | -$70.1M | $13.8M | $8.9M | |
| Diluted EPS | -$189.29 | -$130.73 | -$22.00 | -$3.53 | -$2.90 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.5B | $3.3B | $3.8B | $974.5M | $788.2M | |
| Total Assets | $2.5B | $5.3B | $4.8B | $1.1B | $895.7M | |
| Current Liabilities | $1.2B | $3.4B | $4B | $1.3B | $1.1B | |
| Total Liabilities | $3B | $3.4B | $4B | $1.3B | $1.3B | |
| Total Equity | -$519.8M | $1.8B | $803.9M | -$242M | -$393M | |
| Total Debt | $200M | -- | $303.9M | $66.4M | $208.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$865.3M | -$2.2B | -$95.5M | -$48.7M | -$21M | |
| Cash From Investing | $890.2M | $631.2M | $51.7M | $198.4M | $63.2M | |
| Cash From Financing | $471.8M | -$223.8M | $19.3M | -$275.5M | -$2.7M | |
| Free Cash Flow | -$889.1M | -$2.2B | -$98.8M | -$48.8M | -$22.1M | |
NEUE
Sector
Market Cap
$61.2M
$34.4M
Price % of 52-Week High
89.56%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
48.38%
-1.01%
1-Year Price Total Return
32.43%
-37.36%
Beta (5-Year)
--
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$6.84
200-day SMA
Buy
Level
$6.34
Bollinger Bands (100)
Buy
Level
6.22 - 7.18
Chaikin Money Flow
Sell
Level
-9.2K
20-day SMA
Buy
Level
$6.85
Relative Strength Index (RSI14)
Buy
Level
53.11
ADX Line
Sell
Level
12.32
Williams %R
Neutral
Level
-45
50-day SMA
Buy
Level
$6.83
MACD (12, 26)
Buy
Level
1.87
25-day Aroon Oscillator
Buy
Level
4
On Balance Volume
Sell
Level
-4K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-10.1681)
Sell
CA Score
(Annual)
Level (-4.7752)
Buy
Beneish M-Score
(Annual)
Level (-2.4168)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (13.509)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
NeueHealth Inc is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated healthcare. It consists of two reportable segments: NeueCare - it's a value-driven care delivery business that manages risk in partnership with external payors and serves all populations across The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act. NeueSolutions - it's a provider enablement business that includes a suite of technology, services, and clinical care solutions that empower providers to thrive in performance-based arrangements.
Stock Forecast FAQ
In the current month, NEUE has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The NEUE average analyst price target in the past 3 months is $7.00.
-
Where Will NeueHealth Stock Be In 1 Year?
According to analysts, the consensus estimate is that NeueHealth share price will rise to $7.00 per share over the next 12 months.
-
What Do Analysts Say About NeueHealth?
Analysts are divided on their view about NeueHealth share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that NeueHealth is a Sell and believe this share price will drop from its current level to $7.00.
-
What Is NeueHealth's Price Target?
The price target for NeueHealth over the next 1-year time period is forecast to be $7.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is NEUE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for NeueHealth is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of NEUE?
You can purchase shares of NeueHealth via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase NeueHealth shares.
-
What Is The NeueHealth Share Price Today?
NeueHealth was last trading at $6.87 per share. This represents the most recent stock quote for NeueHealth. Yesterday, NeueHealth closed at $6.86 per share.
-
How To Buy NeueHealth Stock Online?
In order to purchase NeueHealth stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
